Search results
What Medicare beneficiaries need to know about generic medications
Fortune via Yahoo Finance· 14 hours agoShe also recommends looking for an “authorized generic,” which means it’s been authorized by the...
What's the Difference Between Biotech Stocks and TechBio Stocks?
Motley Fool via Yahoo Finance· 3 hours agoBut investors should probably not yet think of TechBio as being a different type of investment than...
Indiana hospital prices 8th-highest in nation, study finds, but hospitals dismiss analysis
Indiana Capital Chronicle via Yahoo News· 1 day agoU.S. Sen. Mike Braun — the Republican nominee for Indiana governor — made a surprise appearance at...
Suze Orman says an HSA is ‘one of the best retirement accounts out there.’ Here’s why she thinks...
Moneywise via AOL· 2 days agoA 65-year-old “can expect to spend an average of $157,500 in healthcare and medical expenses...
AI chip company Cerebras announces major advances in materials science, sparse training and more -...
SiliconANGLE· 3 hours agoArtificial intelligence chip startup Cerebras Systems Inc. says it’s getting some serious traction...
29. Alto Pharmacy
CNBC· 1 day agoAlto is a full-service pharmacy backed by a digital platform started by former Facebook employees, and is among those looking to transform drug...
Which Allergy Medicine Is Actually Most Effective?
Good Housekeeping via Yahoo News· 5 days agoDoctors on the differences of Zyrtec vs. Claritin, plus how to choose the right medication for you if you are sneezing and itching from seasonal...
Q1 2024 Talphera Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 2 hours agoIn addition, the research continues to support uptake of Niyad at a competitive price to the total cost of citrate anticoagulation. This total cost of citrate ...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 1 day agoHemgenix gained U.S. approval in late 2022 and also costs $3.5 million before insurance deductions...
Undervalued by 28%, This Stock Is a Buy for Patient Investors
Morningstar· 7 days agoBiogen BIIB is having a tough year: Its shares are down 15% through early May. The wide-moat...
